ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2021
Asthma and COVID-19: a systematic review.
Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Asthma and COVID-19 risk: a systematic review and meta-analysis.The European respiratory journal · 2022Pooled it
- Covid-19 and non-communicable diseases: evidence from a systematic literature review.BMC public health · 2021Pooled it
- Changes in patient conceptualization of asthma and asthma self-management at key timepoints across the COVID-19 pandemic: A qualitative study.British journal of health psychology · 2026Article
- Prognostic Value of Charlson Comorbidity Index in Patients with COVID-19.Tropical medicine and infectious disease · 2026Article
- Treatment of Severe Asthma: Case Report of Fast Action of Mepolizumab in a Patient with Recent SARS-CoV-2 Infection.Life (Basel, Switzerland) · 2024Article
- Comprehensive analysis of clinical data for COVID-19 outcome estimation with machine learning models.Biomedical signal processing and control · 2023Article
- Incident and recurrent depression among older adults with asthma during the COVID-19 pandemic: Findings from the Canadian Longitudinal Study on Aging.Respiratory medicine · 2023Article
- Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality.Clinical reviews in allergy & immunology · 2023Review
- Asthma and COVID-19 Outcomes: A Prospective Study in a Large Health Care Delivery System.Journal of asthma and allergy · 2023Article
- Management of chronic respiratory diseases during viral pandemics: A concise review of guidance and recommendations.Journal of family medicine and primary care · 2022Review
- Environmental contributions to the interactions of COVID-19 and asthma: A secondary publication and update.The World Allergy Organization journal · 2022Review
- Modelling of a triage scoring tool for SARS-COV-2 PCR testing in health-care workers: data from the first German COVID-19 Testing Unit in Munich.BMC infectious diseases · 2022Article
- A machine learning-driven spatio-temporal vulnerability appraisal based on socio-economic data for COVID-19 impact prevention in the U.S. counties.Sustainable cities and society · 2022Article
- Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization.Internal and emergency medicine · 2022Article
- Evaluation of Antibacterial and Antiviral Drug Effectiveness in COVID-19 Therapy: A Data-Driven Retrospective Approach.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Article
- School Asthma Care During COVID-19: What We Have Learned and What We Are Learning.The journal of allergy and clinical immunology. In practice · 2022Article
- Clinical Features and Outcomes Associated with Bronchial Asthma Among COVID-19 Hospitalized Patients.Journal of asthma and allergy · 2022Article
- Article
- Profile of coronavirus disease enlightened asthma as a protective factor against death: An epidemiology study from Brazil during the pandemic.Frontiers in medicine · 2022Article
- Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here.BMC public health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSevere coronavirus disease-19 (COVID-19) presents with progressive dyspnea, which results from acute lung inflammatory edema leading to hypoxia. As with other infectious diseases that affect the respiratory tract, asthma has been cited as a potential risk factor for severe COVID-19. However, conflicting results have been published over the last few months and the putative association between these two diseases is still unproven.
methodsHere, we systematically reviewed all reports on COVID-19 published since its emergence in December 2019 to June 30, 2020, looking into the description of asthma as a premorbid condition, which could indicate its potential involvement in disease progression.
resultsWe found 372 articles describing the underlying diseases of 161,271 patients diagnosed with COVID-19. Asthma was reported as a premorbid condition in only 2623 patients accounting for 1.6% of all patients.
conclusionsAs the global prevalence of asthma is 4.4%, we conclude that either asthma is not a premorbid condition that contributes to the development of COVID-19 or clinicians and researchers are not accurately describing the premorbidities in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.